Donald Edward Tsai, M.D., Ph.D.
Associate Professor of Medicine at the Hospital of the University of Pennsylvania
Attending Physician, Hospital of the University of Pennsylvania, Philadelphia, PA
Department: Medicine
Contact information
Perelman Center for Advanced Medicine
2 West Pavilion
3400 Civic Center Boulevard
Philadelphia, PA 19104
2 West Pavilion
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-614-0037
Fax: 215-662-4064
Fax: 215-662-4064
Email:
detsai@mail.med.upenn.edu
detsai@mail.med.upenn.edu
Education:
A.B. (Biochemistry)
Harvard College, Cambridge, MA, 1986.
Ph.D. (Microbiology & Immunology)
Duke University, Durham, NC, 1993.
M.D. (Medicine)
Duke University School of Medicine, Durham, NC, 1994.
A.B. (Biochemistry)
Harvard College, Cambridge, MA, 1986.
Ph.D. (Microbiology & Immunology)
Duke University, Durham, NC, 1993.
M.D. (Medicine)
Duke University School of Medicine, Durham, NC, 1994.
Post-Graduate Training
Intern in Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 1994-1995.
Resident in Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 1995-1996.
Post doctoral Fellowship, Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, 1996-2000.
Intern in Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 1994-1995.
Resident in Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 1995-1996.
Post doctoral Fellowship, Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, 1996-2000.
Certifications
Internal Medicine, American Board of Internal Medicine, 1997.
Medical Oncology, American Board of Internal Medicine, 2001.
Permanent linkInternal Medicine, American Board of Internal Medicine, 1997.
Medical Oncology, American Board of Internal Medicine, 2001.
Description of Research Expertise
Posttransplant Lymphoproliferative DisorderDescription of Clinical Expertise
Hematologic Malignancy and Stem Cell TransplantationSelected Publications
Murashimo M, Milone M, Shaw LM, Tsai D, Bloom R: Methotrexate clearance by high-flux hemodialysis and peritoneal dialysis: a case report. American Journal of Kidney Diseases 2009 Notes: accepted.Tsai DE, Douglas L, Andreadis C, Vogl DT, Arnoldi S, Kotloff R, Svoboda J, Blood RD, Olthoff KM, Brozena SC, Schuster SJ, Stadtmauer EA, Robertson ES, Wasik MA, Ahya VN: EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. American Journal of Transplantation 8: 1016-1024, 2008.
Lan K, Murakami M, Choudhuri T, Tsai DE, Schuster SJ, Wasik MA, Robertson ES: Detection of Epstein-Barr virus in T-cell prolymphocytic leukemia cells in vitro. Journal of Clinical Virology 43: 250-265, 2008.
DiNardo CD, Ky B, Vogl DT, Forfia P, Loren A, Luger S, Mato A, Tsai DE. : Differentiation Syndrome in Non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene. Medical Oncology 25: 299-302, 2008.
Tsai DE, Mato A, Porter DL, Vogl DT: Hypertriglyceridemia presenting as “pink blood” and elevated hemoglobin level. American Journal of Hematology 83: 253, 2008.
SE, Downs LH, Torigian DA, Chong EA, Tsai DE, Wasik, MA, Schuster SJ: Successful treatment of relapsed lymphomatoid granulomatosis with bexarotene. Cancer Biology & Therapy 7: 1544-1546, 2008.
Olin RL, Vogl DT, Porter DL, Luger SM, Schuscter SJ, Tsai DE, Siegel DL, Cook RJ, Mangan PA, Cunningham K, Stadtmauer EA: Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplantation 2008 Notes: accepted for publication.
Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, Pullman-Mooar S, Barnack F, Striebich, Looney RJ, Prak ETL, Kimberly R, Zhang Y, Eisenberg R. : Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Annals of the Rheumatic Diseases 67: 1724-1731, 2008.
Murashimo M, Drott HR, Carlow D, Shaw LM, Milone M,Tsai DE, Yang SL, Bloom RD: Removal of gadolinium by peritoneal dialysis. Clinical Nephrology 69: 368-373, 2008.
Tsai DE, Luger SM, Kemner A, Andreadis C, Vogl DT, Potuzak M, Goradia A, Loren AW, Perl AE, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Thompson JE, Swider C, Bagg A, Nowell P, Carroll M: A phase I study of bexarotene, a retinoic X receptor agonist in non-M3 acute myeloid leukemia. Clinical Cancer Research 14: 5619-5625, 2008.
